Abstract

Curettage of benign bone tumor is a common cause for bone defect. For such bone defect repair, autogenous bone, allogeneic bone and traditional artificial bone graft substitutes have many disadvantages. In recent years, a biomimetic mineralized collagen (MC) with similar composition and microstructures to the natural bone matrix was developed and used for treating various bone defects. In this work, a retrospective study analyzed clinical outcomes of patients treated with curettage of benign bone tumors and bone grafting with MC, in comparison to another group treated with the same surgical method and autogenous bone. Lane–Sandhu X-ray score of the autogenous bone group was superior to the MC group at 1 month after the operation, but the two groups had no statistical difference at 6 and 12 months. The MC group was better in Musculoskeletal Tumor Society scoring at 1 and 6 months after the operation, and the two groups had no statistical difference at 12 month. Therefore, the MC performed not as good as autogenous bone in early stage of bone healing but achieved comparable outcomes in long-term follow-ups. Moreover, the MC has advantages in function recovery and avoided potential complications induced by harvesting autogenous bone.

中文翻译：

---

刮除良性骨肿瘤后矿化胶原蛋白骨移植的临床观察

抽象的

刮除良性骨肿瘤是造成骨缺损的常见原因。对于这样的骨缺损修复，自体骨，同种异体骨和传统的人造骨移植替代物具有许多缺点。近年来，具有与天然骨基质相似的组成和微结构的仿生矿物质化胶原蛋白（MC）被开发并用于治疗各种骨缺损。在这项工作中，与另一组采用相同手术方法和自体骨治疗的组相比，一项回顾性研究分析了良性骨肿瘤刮除术和MC植骨治疗的患者的临床结局。术后1个月，自体骨组的Lane-Sandhu X射线评分优于MC组，但两组在6和12个月时无统计学差异。术后1个月和6个月，MC组的肌肉骨骼肿瘤协会评分较高，两组在12个月时无统计学差异。因此，在骨愈合的早期阶段，MC的表现不如自体骨，但在长期随访中却取得了可比的结果。此外，MC在功能恢复方面具有优势，并且避免了由于收获自体骨而引起的潜在并发症。